-- Long-term safety and sustained anti-VEGF protein expression out to 30 months following a single IVT injection of ADVM-022 in NHPs -- REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adverum ...
-The Phase 2 LUNA trial is expected to dose the first subject in the third quarter of 2022 and preliminary data anticipated throughout 2023 “We are pleased to present our findings on BCVA and CST from ...
A panel of ophthalmologists defined points of consensus for suprachoroidal space injections based on current published evidence. IVT is the primary method of delivering therapeutics in the eye, ...
-- Company to host conference call with Key Opinion Leader Dr. Arshad M. Khanani today at 1:30 pm PT / 4:30 pm ET-- REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, ...
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision ...
-The Phase 2 LUNA trial is expected to dose the first subject in the third quarter of 2022 and preliminary data anticipated throughout 2023 REDWOOD CITY, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results